This company has been marked as potentially delisted and may not be actively trading. ContraFect (CFRX) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock CFRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period 22R.BE,0P0001D9RF,0 (22R.BE)September 22, 2024 | nz.finance.yahoo.comRegenETP, Inc. (RGTPQ)April 16, 2024 | finance.yahoo.comContraFect Corp CFRXQJanuary 9, 2024 | morningstar.comMContraFect Corp CFRXNovember 19, 2023 | morningstar.comMContraFect: Q3 Earnings SnapshotNovember 14, 2023 | washingtonpost.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 23, 2023 | benzinga.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | msn.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyOctober 16, 2023 | finance.yahoo.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketOctober 10, 2023 | benzinga.comCFRX: IND Application for CF-370 Submitted to FDA…September 21, 2023 | finance.yahoo.comAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | markets.businessinsider.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 19, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370September 18, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 28, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 17, 2023 | finance.yahoo.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 15, 2023 | markets.businessinsider.comContraFect: Q2 Earnings SnapshotAugust 14, 2023 | sfgate.comContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comContraFect CorpJuly 25, 2023 | money.usnews.comContraFect (CFRX) Price Target Decreased by 97.37% to 5.10July 6, 2023 | msn.comContraFect enters a warrant exercise transaction for $9.6MJune 27, 2023 | msn.comContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionJune 27, 2023 | finance.yahoo.com8-K: CONTRAFECT CorpJune 22, 2023 | marketwatch.comCFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…June 22, 2023 | finance.yahoo.comContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensJune 20, 2023 | finance.yahoo.comContraFect Gains with Key Data Presentation Set for Next WeekJune 9, 2023 | msn.comContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023June 8, 2023 | finance.yahoo.comCFRX: First Patient Dosed in Phase 1b/2 Trial of Exebacase for the Treatment of Chronic Prosthetic Joint Infections…May 23, 2023 | finance.yahoo.comContraFect Corporation: ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | finanznachrichten.deContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 15, 2023 | finance.yahoo.comWhat's Going On With ContraFecta Stock TodayApril 27, 2023 | finance.yahoo.comContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeApril 26, 2023 | finance.yahoo.comContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative PathogensApril 20, 2023 | finance.yahoo.comWhy Is ContraFect (CFRX) Stock Down 14% Today?April 18, 2023 | investorplace.comContraFect (Nasdaq:CFRX) HeadlineTrading was temporarily halted for "CFRX" at 12:04 PM with a stated reason of "LULD pause."...April 14, 2023 | marketbeat.comMaxim Group upgrades ContraFect (CFRX) to a BuyApril 13, 2023 | markets.businessinsider.comCFRX: Initiates Phase 1 Trial for Exebacase in Chronic Prosthetic Joint Infection…April 13, 2023 | finance.yahoo.comIs ContraFect Corp (CFRX) a Bad Choice in Biotechnology Monday?April 12, 2023 | benzinga.comContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID MeetingApril 6, 2023 | finance.yahoo.comContraFect Corporation: ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateApril 1, 2023 | finanznachrichten.deContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateMarch 31, 2023 | finance.yahoo.comContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private PlacementFebruary 28, 2023 | finance.yahoo.comContraFect (Nasdaq:CFRX) HeadlineTrading was temporarily halted for "CFRX" at 09:02 AM with a stated reason of "LULD pause."...February 27, 2023 | marketbeat.comContraFect (Nasdaq:CFRX) HeadlineTrading was temporarily halted for "CFRX" at 09:02 AM with a stated reason of "LULD pause."...February 27, 2023 | marketbeat.comContraFect (NASDAQ:CFRX) Now Covered by Analysts at StockNews.comFebruary 16, 2023 | marketbeat.comContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection StudyDecember 20, 2022 | finance.yahoo.comContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of ExebacaseDecember 19, 2022 | finance.yahoo.comContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private PlacementDecember 13, 2022 | finance.yahoo.comCFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection…November 30, 2022 | finance.yahoo.comContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint InfectionsNovember 28, 2022 | finance.yahoo.com Get ContraFect News Delivered to You Automatically Sign up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CFRX Media Mentions By Week CFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CFRX News Sentiment▼0.000.79▲Average Medical News Sentiment CFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CFRX Articles This Week▼00▲CFRX Articles Average Week Get the Latest News and Ratings for CFRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ContraFect and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies VCNX News Today EVFM News Today PTPI News Today HEPA News Today BPTH News Today TRVN News Today VINC News Today SYRS News Today VRPX News Today CURX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CFRX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraFect With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
